Gr. Upchurch et al., PROTHROMBOTIC CONSEQUENCES OF THE OXIDATION OF FIBRINOGEN AND THEIR INHIBITION BY ASPIRIN, Journal of thrombosis and thrombolysis, 5(1), 1998, pp. 9-14
Oxidant stress leads to covalent oxidative modification of several pla
sma proteins, chief among which is fibrinogen. Aspirin can nonenzymati
cally acetylate fibrinogen's lysine residues, the functional groups mo
st susceptible to oxidative modification. Because oxidation of fibrino
gen may occur in the atheromatous environment, we studied the effects
of oxidative modification on fibrinogen function and the consequences
of acetylation by aspirin on fibrinogen's susceptibility to oxidation
and functional properties. We exposed fibrinogen to Fe3+ ascorbate for
1 hour and showed that the carbonyl/protein molar ratio increased fro
m 0.71 +/- 0.18 to 2.86 +/- 0.50 mol carbonyl/mol protein (P < 0.02) w
ith an accompanying reduction in the cu helical content of the protein
from 34% to 29%. Exposure of fibrinogen to aspirin led to acetylation
of lysine residues and inhibition of oxidation. Oxidized fibrinogen w
as more readily able to form fibrin, and acetylation prevented this en
hancement of clot formation. Oxidized fibrinogen also supported platel
et aggregation better than did native, unoxidized fibrinogen, and acet
ylation of fibrinogen prior to oxidation prevented the enhanced platel
et aggregation. Oxidized fibrinogen was less effective in stimulating
plasminogen activation by tissue type plasminogen activator (t-PA), wi
th a catalytic efficiency that was reduced by 88% compared with native
, unoxidized fibrinogen; acetylated fibrinogen, by contrast, enhanced
plasminogen activation by t-PA with a catalytic efficiency that was in
creased by 18% compared with native, unoxidized fibrinogen (P < 0.05)
and was increased by 51% compared with oxidized fibrinogen (P < 0.05).
Acetylation prevented the reduction in catalytic efficiency induced b
y oxidation. These data show that oxidized fibrinogen manifests prothr
ombotic effects that can be prevented by acetylation and suggest that
inhibition of fibrinogen oxidation may be an additional antithrombotic
benefit of aspirin therapy.